Latest Gilead Sciences Stories
Among heterosexual African couples in which the male was HIV positive and the female was not, receipt of antiretroviral pre-exposure preventive (PrEP) therapy did not result in significant differences in pregnancy incidence, birth outcomes, and infant growth compared to females who received placebo.
SOUTH SAN FRANCISCO, Calif., June 23, 2014 /PRNewswire/ -- Tobira Therapeutics, a clinical-stage biopharmaceutical company advancing cenicriviroc (CVC) in liver disease and HIV, announced today
A new combination therapy could cut treatment time for hepatitis C to just four weeks, but quicker recovery comes with a steep price, as the new medication is said to cost roughly $1,000 per pill.
HAYWARD, Calif., June 13, 2014 /PRNewswire/ -- Anthera Pharmaceuticals, Inc.
Agreement is ViiV Healthcare's first external collaboration for development of a two drug single-tablet combining dolutegravir and rilpivirine LONDON, June 12, 2014 /PRNewswire/ -- ViiV Healthcare
CORK, Ireland, June 12, 2014 /PRNewswire/ -- Janssen R&D Ireland Ltd announced today that they have entered into a collaboration with ViiV Healthcare to develop and
In-demand research report “Chronic Lymphocytic Leukaemia: KOL Insight” worked out by FirstWord is now available at MarketPublishers.com. London, UK (PRWEB)
LONDON, June 4, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
LONDON, May 28, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
LONDON, May 26, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
- A ceramic container used inside a fuel-fired kiln to protect pots from the flame.